Skip Navigation

Michael Hassett, MD, MPH


Medical Oncology

Make an Appointment

Physician

  • Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Breast cancer

Diseases Treated

Contact Information

  • Appointments617-632-2175 (new)
    617-632-3800 (follow-up)
  • Office Phone Number617-632-3800
  • Fax617-632-1930

Board Certification:

  • Internal Medicine, 2001
  • Medical Oncology, 2005

Fellowship:

  • Dana-Farber/Partners CancerCare

Residency:

  • University of Rochester Medical Center/Strong Memorial Hospital, Chief Medical Resident
  • University of Rochester Medical Center/Strong Memorial Hospital, Internal Medicine

Medical School:

  • State University of New York, Buffalo School of Medicine

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions

Research

Health services research, Breast oncology

The main focus of my work involves measuring and improving quality of care, assessing outcomes, evaluating spending, and characterizing the value of cancer care.  Current major research projects include evaluating the quality of care offered to minority and economically disadvantaged women with breast cancer using linked cancer registry-Medicaid claims data, developing algorithms that identify patients with recurrent cancer using claims/electronic health record data, and studying the impact of initial treatment decisions for DCIS on the odds and type of recurrence.  Recently, I have published on the adoption of gene expression profile testing and its association with the use of chemotherapy among women with hormone-receptor positive breast cancer.  The long term goals of my work are to understand how healthcare policies, systems of care, and reimbursement models improve quality, impact outcomes, and increase value.

Uno H, Hassett MJ, Wei LJ. Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer. JAMA. 2018 01 16; 319(3):306.
View in: PubMed

Poorvu PD, Vaz-Luis I, Freedman RA, Lin NU, Barry WT, Winer EP, Hassett MJ. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018 Jan 13.
View in: PubMed

Hassett MJ, Uno H, Cronin AM, Carroll NM, Hornbrook MC, Ritzwoller D. Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care. 2017 12; 55(12):e88-e98.
View in: PubMed

Punglia RS, Jiang W, Lipsitz SR, Hughes ME, Schnitt SJ, Hassett MJ, Nekhlyudov L, Achacoso N, Edge S, Javid SH, Niland JC, Theriault RL, Wong YN, Habel LA. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat. 2018 Feb; 167(3):751-759.
View in: PubMed

Hassett MJ. Usability Considerations in Oncology Electronic Medical Records. J Oncol Pract. 2017 Aug; 13(8):539-541.
View in: PubMed

Chen CT, Li L, Brooks G, Hassett M, Schrag D. Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death. Health Serv Res. 2017 Jul 26.
View in: PubMed

Hassett MJ. Quality Improvement in the Era of Big Data. J Clin Oncol. 2017 Oct 01; 35(28):3178-3180.
View in: PubMed

Hassett MJ, Uno H, Cronin AM, Carroll NM, Hornbrook MC, Fishman P, Ritzwoller DP. Survival after recurrence of stage I-III breast, colorectal, or lung cancer. Cancer Epidemiol. 2017 08; 49:186-194.
View in: PubMed

Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78.
View in: PubMed

Lynch JA, Berse B, Petkov V, Filipski K, Zhou Y, Khoury MJ, Hassett M, Freedman AN. Implementation of the 21-gene recurrence score test in the United States in 2011. Genet Med. 2016 Oct; 18(10):982-90.
View in: PubMed

Hassett MJ, Jiang W, Habel LA, Nekhlyudov L, Achacoso N, Acton L, Schnitt SJ, Schrag D, Punglia RS. Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. Breast Cancer Res Treat. 2016 Feb; 155(3):541-9.
View in: PubMed

Ganz PA, Hassett MJ, Miller DC. Challenges and Opportunities in Delivering High-Quality Cancer Care: A 2016 Update. Am Soc Clin Oncol Educ Book. 2016; 35:e294-300.
View in: PubMed

Hassett MJ, Schymura MJ, Chen K, Boscoe FP, Gesten FC, Schrag D. Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment. Cancer. 2016 Feb 01; 122(3):420-31.
View in: PubMed

Hassett MJ, Uno H, Cronin AM, Carroll NM, Hornbrook MC, Ritzwoller D. Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care. 2015 Jul 29.
View in: PubMed

Tseng YD, Uno H, Hughes ME, Niland JC, Wong YN, Theriault R, Blitzblau RC, Moy B, Breslin T, Edge SB, Hassett MJ, Punglia RS. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):622-30.
View in: PubMed

Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48.
View in: PubMed

Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, Schrag D, Warren JL, Hornbrook MC, Weeks JC. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2014 Oct; 52(10):e65-73.
View in: PubMed

Brooks GA, Li L, Uno H, Hassett MJ, Landon BE, Schrag D. Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer. Health Aff (Millwood). 2014 Oct; 33(10):1793-800.
View in: PubMed

Hassett MJ, Neville BA, Weeks JC. The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst. 2014 Oct; 106(10).
View in: PubMed

Hassett MJ, McNiff KK, Dicker AP, Gilligan T, Hendricks CB, Lennes I, Murray T, Krzyzanowska MK. High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit. J Oncol Pract. 2014 May; 10(3):e160-6.
View in: PubMed

Dalby CK, Anastas S, Brady L, Hassett MJ, Shulman LN, Jacobson JO. Implementation of chemotherapy treatment plans (CTP) in a large comprehensive cancer center (CCC): The key roles of infrastructure and data sharing. J Clin Oncol. 2013 Nov; 31(31_suppl):20.
View in: PubMed

Hassett MJ, Elkin EB. What does breast cancer treatment cost and what is it worth? Hematol Oncol Clin North Am. 2013 Aug; 27(4):829-41, ix.
View in: PubMed

Weingart SN, Zhu J, Young-Hong J, Vermilya HB, Hassett M. Do drug interaction alerts between a chemotherapy order-entry system and an electronic medical record affect clinician behavior? J Oncol Pharm Pract. 2014 Jun; 20(3):163-71.
View in: PubMed

Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, Punglia RS. Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst. 2013 Jun 05; 105(11):774-81.
View in: PubMed

Brooks GA, Li L, Sharma DB, Weeks JC, Hassett MJ, Yabroff KR, Schrag D. Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst. 2013 May 01; 105(9):634-42.
View in: PubMed

Hassett MJ, Wheelock A, Thorsen CM, Kaplan C, Ozanne E. Cost of cancer care: The impact of disclosure on willingness to pay and treatment preferences. J Clin Oncol. 2012 Dec; 30(34_suppl):15.
View in: PubMed

Abel GA, Chen K, Taback N, Hassett MJ, Schrag D, Weeks JC. Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions. Cancer. 2013 Mar 01; 119(5):1065-72.
View in: PubMed

Weingart SN, Mattsson T, Zhu J, Shulman LN, Hassett M. Improving electronic oral chemotherapy prescription: can we build a safer system? J Oncol Pract. 2012 Nov; 8(6):e168-73.
View in: PubMed

Yung RL, Hassett MJ, Chen K, Gesten FC, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, Schrag D. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1102-5.
View in: PubMed

Arvold ND, Punglia RS, Hughes ME, Jiang W, Edge SB, Javid SH, Laronga C, Niland JC, Theriault RL, Weeks JC, Wong YN, Lee SJ, Hassett MJ. Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer. 2012 Dec 15; 118(24):6022-30.
View in: PubMed

Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012 Jun 20; 30(18):2218-26.
View in: PubMed

Weingart SN, Li JW, Zhu J, Morway L, Stuver SO, Shulman LN, Hassett MJ. US Cancer Center Implementation of ASCO/Oncology Nursing Society Chemotherapy Administration Safety Standards. J Oncol Pract. 2012 Jan; 8(1):7-12.
View in: PubMed

Stuver SO, Zhu J, Simchowitz B, Hassett MJ, Shulman LN, Weingart SN. Identifying women at risk of delayed breast cancer diagnosis. Jt Comm J Qual Patient Saf. 2011 Dec; 37(12):568-75.
View in: PubMed

Brawarsky P, Neville BA, Fitzmaurice GM, Hassett MJ, Haas JS. Use of annual mammography among older women with ductal carcinoma in situ. J Gen Intern Med. 2012 May; 27(5):500-5.
View in: PubMed

Elkin EB, Marshall DA, Kulin NA, Ferrusi IL, Hassett MJ, Ladabaum U, Phillips KA. Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011 Oct; 13(10):853-60.
View in: PubMed

Arnaout A, Leblebjian H, Bartel S, Hassett MJ. Relative dose intensity (RDI) assessment in an academic center. J Clin Oncol. 2011 Sep 20; 29(27_suppl):139.
View in: PubMed

Haas JS, Liang SY, Hassett MJ, Shiboski S, Elkin EB, Phillips KA. Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat. 2011 Nov; 130(2):619-26.
View in: PubMed

Yung RL, Hassett MJ, Chen K, Gesten FC, Roohan PR, Boscoe FP, Sinclair AH, Schymura MJ, Schrag D. Adjuvant hormone therapy use in early-stage breast cancer patients insured by the New York State Medicaid program. J Clin Oncol. 2011 May 20; 29(15_suppl):6031.
View in: PubMed

Arvold ND, Punglia RS, Hughes ME, Jiang W, Edge SB, Javid SH, Laronga C, Niland JC, Theriault RL, Weeks JC, Wong Y, Lee SJ, Hassett MJ. Pathologic characteristics of second breast cancers (SBC) among women previously treated for ductal carcinoma in situ (DCIS) with breast conservation. J Clin Oncol. 2011 May 20; 29(15_suppl):1042.
View in: PubMed

Hassett MJ, Neville BA, Weeks JC. The relationship between cost, quality, and outcomes among women with breast cancer in SEER-Medicare. J Clin Oncol. 2011 May 20; 29(15_suppl):6001.
View in: PubMed

Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M. Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract. 2011 May; 7(3 Suppl):e1s-7s.
View in: PubMed

Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M. Genomic testing and therapies for breast cancer in clinical practice. Am J Manag Care. 2011 May 01; 17(5 Spec No):e174-81.
View in: PubMed

Hassett MJ, Rao SR, Brozovic S, Stahl JE, Schwartz JH, Maloney B, Jacobson JO. Chemotherapy-related hospitalization among community cancer center patients. Oncologist. 2011; 16(3):378-87.
View in: PubMed

Hu YY, Weeks CM, In H, Dodgion CM, Golshan M, Chun YS, Hassett MJ, Corso KA, Gu X, Lipsitz SR, Greenberg CC. Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer. 2011 Jul 01; 117(13):2833-41.
View in: PubMed

Punglia RS, Hassett MJ. Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. J Clin Oncol. 2010 Sep 20; 28(27):4108-10.
View in: PubMed

Hassett MJ. The full burden of cancer. Oncologist. 2010; 15(8):793-5.
View in: PubMed

Phillips KA, Marshall DA, Haas JS, Elkin EB, Liang SY, Hassett MJ, Ferrusi I, Brock JE, Van Bebber SL. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009 Nov 15; 115(22):5166-74.
View in: PubMed

Hassett MJ, O'Malley AJ, Keating NL. Factors influencing changes in employment among women with newly diagnosed breast cancer. Cancer. 2009 Jun 15; 115(12):2775-82.
View in: PubMed

Hassett MJ, Weeks JC. Identifying high-priority quality measures for breast cancer quality improvement using data from a nationally representative sample. J Clin Oncol. 2009 May 20; 27(15_suppl):6507.
View in: PubMed

Haas J, Phillips KA, Hassett MJ, Liang S, Keohane C, Armstrong J, Toscano M. Breast cancer testing strategies and the utilization of targeted therapies: Data from the real world. J Clin Oncol. 2009 May 20; 27(15_suppl):e17518.
View in: PubMed

Rao SR, Hassett M, Schwartz JH, Maloney B, Jacobson JO. Admissions for chemotherapy-related serious adverse effects (CR-SAEs) and rates of mortality among community cancer center patients. J Clin Oncol. 2009 May 20; 27(15_suppl):6571.
View in: PubMed

Hassett MJ, Griggs JJ. Disparities in breast cancer adjuvant chemotherapy: moving beyond yes or no. J Clin Oncol. 2009 May 01; 27(13):2120-1.
View in: PubMed

Friese CR, Neville BA, Edge SB, Hassett MJ, Earle CC. Breast biopsy patterns and outcomes in Surveillance, Epidemiology, and End Results-Medicare data. Cancer. 2009 Feb 15; 115(4):716-24.
View in: PubMed

Azzone V, Frank RG, Pakes JR, Earle CC, Hassett MJ. Behavioral health services for women who have breast cancer. J Clin Oncol. 2009 Feb 10; 27(5):706-12.
View in: PubMed

Hassett MJ, Hughes ME, Niland JC, Edge SB, Theriault RL, Wong YN, Wilson J, Carter WB, Blayney DW, Weeks JC. Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. J Clin Oncol. 2008 Dec 01; 26(34):5553-60.
View in: PubMed

Hassett MJ, Hughes ME, Niland JC, Ottesen R, Edge SB, Bookman MA, Carlson RW, Theriault RL, Weeks JC. Selecting high priority quality measures for breast cancer quality improvement. Med Care. 2008 Aug; 46(8):762-70.
View in: PubMed

Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006 Aug 16; 98(16):1108-17.
View in: PubMed

Hassett MJ, Pakes J, O'Malley AJ, Newhouse JP, Earle CC. Chemotherapy-related serious adverse events and health care expenditures among commercially insured women with breast cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):6000.
View in: PubMed

Research Departments:

Top